For this, we accessed the cancer therapeutics response portal v2 (CTRP v2) resulting from 37 breast cancer cell lines treated with the COX-2 selective inhibitor, valdecoxib (http://portals.broadinstitute.org/ctrp/). Here, PTGS2 is linked to breast carcinoma.